12月4日，第六届筑梦者公益大会在北京召开。为致敬在公益领域做出杰出贡献的机构与个人，大会发 布了"年度筑梦者名单"。凭借近年来的突出公益贡献与良好的社会效益，爱尔眼科荣获"年度公益贡 献"奖。 成立二十余年以来，爱尔眼科在谋求自身发展的同时，积极践行社会责任，将"输血"与"造血"有机结 合，凭借人才、技术、资源等多方面优势，全力助推乡村振兴、关怀弱势群体、促进医疗与教育普惠。 目前，爱尔眼科已累计支持公益项目873项，公益足迹遍及全国31个省、自治区及直辖市的300多个地 区，并三届蝉联"中华慈善奖"。 爱尔眼科荣获"年度公益贡献"奖 未来，爱尔眼科将积极发挥自身优势，继续深化可持续公益模式，让光明覆盖更多角落，为健康中国建 设贡献坚实的"爱尔力量"。 爱尔眼科首创的"交叉补贴"公益模式，将高端医疗服务所获得的利润补贴至低收入眼病患者群体，为困 难患者提供了长期眼科医疗救助，也为公益事业注入了可持续动力。同时，针对老人、儿童、妇女、残 疾人等弱势人群，爱尔眼科联合社会各界，建立了覆盖白内障、青光眼、眼底病、角膜病、近视防控等 多个病种的眼健康关爱救助体系，为困境患者提供精准救助。 在国家乡村振兴战略的指引下 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-099 理财币种：人民币 爱尔眼科医院集团股份有限公司 关于使用部分闲置自有资金进行现金管理的实施公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日召开第六届董事会第三十二次会议和第六届监事会第二十次会议，审议通过了 《关于使用部分闲置自有资金进行现金管理的议案》，同意公司在保证日常经营 资金需求和资金安全的前提下，使用不超过人民币 15 亿元的闲置自有资金购买 安全性高、流动性好、风险性低的理财产品，期限为自公司第六届董事会第三十 二次会议决议之日起 12 个月。在上述额度及期限内，资金可循环滚动使用，由 公司财务中心负责具体购买事宜。上述内容详见公司 2025 年 3 月 24 日在巨潮资 讯网（www.cninfo.com.cn）披露的相关公告。 根据上述决议，公司于近期办理了投资理财业务。现就具体事项公告如下： 一、本次使用部分暂时闲置自有资金进行现金管理的实施情况 产品名称:中银理财-(14 天)最短持有期固 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting it to outperform the CSI 300 index by more than 10% in the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.25% from November 21 to December 4, 2025, which is approximately 0.85 percentage points lower than the index [4][11]. - Most sub-sectors within the industry recorded negative returns during the same period, with the pharmaceutical distribution and offline pharmacy sectors showing positive growth of 4.18% and 0.37%, respectively. In contrast, the medical research outsourcing and vaccine sectors experienced declines of 4.57% and 4.45% [4][12]. - Approximately 35% of stocks in the industry recorded positive returns, while about 65% saw negative returns during the reporting period [4][13]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 51.20 times as of December 4, 2025, indicating a decline in industry valuation [4][17]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.25% from November 21 to December 4, 2025 [11]. - Most sub-sectors recorded negative returns, with pharmaceutical distribution and offline pharmacies performing relatively well [12]. - About 35% of stocks in the industry had positive returns, while 65% had negative returns [13]. - The industry valuation has decreased, with a PE ratio of 51.20 times [17]. 2. Industry News - The report highlights significant industry news, including the announcement of centralized procurement results for medical consumables in Liaoning Province, which included 799 products [24]. - The report also mentions the release of the "Clinical Blood Use Technical Specifications (2025 Edition)" by the National Health Commission [20]. 3. Company Announcements - Dongcheng Pharmaceutical announced that its subsidiary received a production license for radioactive pharmaceuticals, which is not expected to significantly impact current performance [25]. 4. Weekly Industry Outlook - The report maintains an "Overweight" rating for the industry, suggesting a focus on investment opportunities in the flu-related sector due to increased flu cases compared to the previous year [26][29]. - Recommended stocks include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, scientific services, and traditional Chinese medicine [26][29].

爱尔眼科捐赠500万港元，驰援香港火灾救援。 ...

Group 1 - The "Investment Opportunities in China" roadshow successfully took place in Germany, featuring representatives from five Shenzhen-listed companies engaging with institutional investors [1] - The Shenzhen Stock Exchange (SZSE) organized a total of 11 overseas roadshows in 2025, covering over 50 Shenzhen-listed companies and reaching countries like Singapore, South Korea, Australia, and Germany [1] - The participating companies in the German roadshow represent key sectors such as renewable energy, high-end manufacturing, and healthcare, which are of significant interest to German investors [1] Group 2 - In the Sydney roadshow, six companies from the green low-carbon and high-end manufacturing sectors engaged with nearly 70 representatives from Australian investment institutions, highlighting the shift of Chinese companies from "technology followers" to "standard setters" [2] - During the Singapore roadshow, companies like Mindray Medical and Inovance Technology received positive feedback from foreign investors, who expressed high interest in the global strategies and technological advancements of Chinese firms [2] - The SZSE is actively organizing roadshows in Hong Kong to enhance understanding and trust between Shenzhen-listed companies and foreign investors, facilitating international investment in the Shenzhen market [2][3] Group 3 - The SZSE plans to continue organizing overseas roadshows and activities for foreign investors to enhance their understanding of the investment value of Chinese assets [3] - The exchange aims to improve the quality of services for connecting Shenzhen-listed companies with foreign investors, facilitating cross-border investment activities [3]

Core Insights - The company, Aier Eye Hospital, announced a strategic cooperation framework agreement with iFlytek in 2024 to enhance service quality and explore application scenarios, benefiting more patients [1] - The company has developed the world's first smart glasses for children's vision management, named "Little Qingkui," which utilizes advanced biosensing technology, big data analysis algorithms, an intelligent reminder system, and a cloud data synchronization app for personalized vision monitoring [1] Group 1 - The strategic partnership aims to leverage each party's strengths for innovative integration [1] - The smart glasses provide a scientific and precise solution for myopia prevention and control [1] - The collaboration is expected to improve service quality and expand patient reach [1]

21世纪经济报道记者 杨坪 近日，21 世纪经济报道记者获悉，深交所组织上市公司赴德国举办"投资中国新机遇"—深市上市公司 法兰克福路演交流会。 活动旨在向当地投资者宣介"十五五"时期中国经济高质量发展前景，面对面讲好深市上市公司科技发展 故事，推动当地投资者更好理解中国资本市场发展机遇与投资价值，进一步助力服务中德产业投资合 作。 据悉，今年以来，深交所在香港、新加坡、韩国、澳大利亚、德国等地和境内累计组织已开展11场境外 路演及境外投资者走进上市公司活动，覆盖超50家次深市上市公司，向境外机构投资者多维度展示深市 上市公司投资价值和中国经济高质量发展新机遇。 多家与会的投资机构表示，通过一系列的路演活动，深入了解了企业的经营情况和发展前景，切身感受 到中国企业在全球化、数字化、高端化、绿色化的微观活力，成为重塑全球价值链的重要力量，将持续 关注中国市场的投资机会，对中国资产的长期投资价值充满信心。 据了解，此次参与法兰克福路演交流会的深市上市公司分别为阳光电源、潍柴动力、爱尔眼科、罗博特 科、海亮股份，来自数字经济、高端制造、绿色低碳等新质生产力领域，并在德国或欧洲有本地化业 务。 与会投资者评价中德两国 ...

Group 1 - The core point of the article is that Aier Eye Hospital has disclosed its total number of shareholders, which is 344,788 as of September 30, 2025 [2]

12月2日，深交所组织上市公司赴德国举办"投资中国新机遇"—深市上市公司法兰克福路演交流会，旨 在向当地投资者宣介"十五五"时期中国经济高质量发展前景，面对面讲好深市上市公司科技发展故事， 推动当地投资者更好理解中国资本市场发展机遇与投资价值，进一步服务中德产业投资合作。 阳光电源（300274）、潍柴动力（000338）、爱尔眼科（300015）、罗博特科（300757）、海亮股份 （002203）5家深市上市公司参与本次路演，本次路演与会企业涵盖新能源、高端制造及医疗领域等细 分龙头，与德国"工业4.0"和ESG投资理念高度契合，是德国投资者所重点关注的中国"新质生产力"代 表。 在欧盟"REPowerEU"能源自主战略的政策框架推动下，中德企业的产业协同正从传统领域向新兴赛道 全面拓展，直接投资、跨境并购成为合作"新标配"。 近年来，阳光电源抓住德国市场绿色能源转型机遇，以慕尼黑子公司为核心提供高性能的光伏逆变器与 储能系统及定制化的综合能源解决方案。潍柴动力基于战略转型与结构调整目的，2012年战略重组德国 凯傲集团，双方发挥协同效应，加快开拓中国叉车市场，凯傲集团营收规模从并购初40亿欧元增长至超 ...

Core Points - The Medical Health R Index (480016) closed at 7284.72 points, down 0.42%, with a trading volume of 17.046 billion yuan and a turnover rate of 0.61% [1] - Among the index constituents, 23 stocks rose while 26 fell, with TeBao Bio leading the gainers at 2.85% and Renfu Pharmaceutical leading the decliners at 3.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 87.62, down 2.01%, and a market cap of 261.437 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 60.97, down 0.25%, and a market cap of 404.670 billion yuan [1] - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 199.50, down 0.56%, and a market cap of 241.882 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 128.88, up 0.13%, and a market cap of 106.217 billion yuan [1] - Pianzai Shou (sh600436) with a weight of 3.48%, latest price at 171.48, up 1.33%, and a market cap of 103.457 billion yuan [1] - Aier Eye Hospital (sz300015) with a weight of 3.42%, latest price at 11.35, down 1.30%, and a market cap of 105.843 billion yuan [1] - Kelun Pharmaceutical (sz002422) with a weight of 2.59%, latest price at 34.00, down 0.03%, and a market cap of 54.334 billion yuan [1] - Xinhecheng (sz002001) with a weight of 2.42%, latest price at 24.44, up 0.20%, and a market cap of 75.114 billion yuan [1] - Fosun Pharma (sh600196) with a weight of 2.39%, latest price at 27.05, down 0.15%, and a market cap of 72.235 billion yuan [1] - Ziji Shenzhou (sh688235) with a weight of 2.27%, latest price at 275.20, down 1.59%, and a market cap of 423.995 billion yuan [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 1.159 billion yuan from institutional investors, while retail investors saw a net inflow of 999 million yuan [1] - Detailed capital flow for specific stocks shows: - Health元 (600380) had a net inflow of 34.2431 million yuan from institutional investors [2] - Hengrui Medicine (600276) had a net inflow of 29.9909 million yuan from institutional investors [2] - Long Spring High-tech (000661) had a net inflow of 19.8154 million yuan from institutional investors [2] - The index constituents underwent adjustments, adding four new stocks and removing one [2]